Cambry Kaylor Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S, Riverton, UT 84065 Phone: 801-571-3081 |
Brynnan Halsey, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S Ste 100, Riverton, UT 84065 Phone: 801-571-3081 |
Jessica Marie Roestenburg, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S, Riverton, UT 84065 Phone: 801-285-4000 |
Andie Marie Stevens Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3773 W 12600 S, Riverton, UT 84065 Phone: 801-285-1700 |
Brooklyn Kaye Simon, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S Ste 100, Riverton, UT 84065 Phone: 801-571-3081 |
Nellie Bubb, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3723 W 12600 S, Riverton, UT 84065 Phone: 833-577-3422 |
Savannah Hall Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S Ste 100, Riverton, UT 84065 Phone: 770-822-9115 |
Daniel Patrick Bolton Sr., OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3419 W 12600 S, Riverton, UT 84065 Phone: 801-693-3941 Fax: 866-379-5965 |
News Archive
Medecins Sans Frontieres (MSF) has called on the Brazilian government "to ensure its state-owned drug company steps up production of the only drug for Chagas disease, which affects 10 million people in Latin America," Guardian Health Editor Sarah Boseley writes in her "Global Health Blog" (10/6).
Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor's vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.
Mad cow disease is caused by the accumulation of an abnormal protein, the prion, in the brain of an affected patient. Outside of the brain, very little is known about prions.
XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).
› Verified 7 days ago